PSMA PET/CT-Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study.
Where this comes from
- Record sourced from PubMed, PMID 42392696.
- Also identified by DOI 10.2967/jnumed.126.272108.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Prostate-specific membrane antigen (PSMA) PET/CT may enhance detection of clinically significant prostate cancer (csPCa) in men with negative or equivocal multiparametric MRI (mpMRI), a setting where diagnostic uncertainty persists. This study assessed the diagnostic performance of PSMA PET/CT-guided targeted biopsy (PET-TB) versus systematic biopsy (SB) and explored the value of semiquantitative (SUV<sub>max</sub>) and dynamic total-body PET parameters in predicting csPCa. <b>Methods:</b> This is a prospective, single-center study that enrolled 63 men with PI-RADS 2-3 mpMRI findings between March 2023 and July 2025. All underwent [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT followed by transperineal prostate biopsy. A subset of 11 patients underwent dynamic total-body PET. The primary endpoint was detection of csPCa (International Society of Urological Pathology score of ≥2). We compared diagnostic yields of PET-TB and SB, evaluated predictors via logistic regression, and analyzed dynamic PET data using kinetic modeling. <b>Results:</b> PET-TB detected significantly more csPCa than did SB (37% vs. 21%; <i>P</i> = 0.021), achieving a sensitivity of 96%, a specificity of 49%, a positive predictive value of 57%, and a negative predictive value of 95%. Combining PET-TB with SB increased the csPCa detection rate to 41%. SUV<sub>max</sub> independently predicted csPCa (odds ratio, 51.2; 95% CI, 5.6-2713.9; <i>P</i> = 0.015), with a threshold of 11.4 yielding 100% specificity. In dynamic PET analysis, csPCa showed irreversible kinetics, and <i>K<sub>i</sub></i> /<i>k</i> <sub>3</sub> parameters improved lesion discrimination beyond SUV, especially in equivocal (PRIMARY score 3) lesions. <b>Conclusion:</b> PSMA PET/CT-guided targeted biopsy enhances csPCa detection in men with negative or equivocal mpMRI, with added predictive value from SUV<sub>max</sub> and dynamic PET metrics. These promising findings should be validated in larger multicenter trials.